Complex Regional Pain syndrome (CRPS) Market Snapshot (2023 to 2030)
The global market for complex regional pain syndrome (CRPS) is estimated to be worth US$ 101.9 Million in 2023, rising to US$ 126.7 Million by 2030. During the projection period of 2023 to 2030, the market is forecast to grow at a CAGR of 2.2%.
The increase in the number of people suffering from the complex regional pain syndrome (CRPS), chronic pain and back failure syndrome is one of the major reasons for the development of the market. Complex Regional Pain Syndrome (CRPS) is a chronic pain disorder that can affect the whole body or just the legs, arms, feet, and hands. There are two forms of CRPS, each with identical symptoms and treatments. Complex regional pain syndrome (CRPS) type I occurs after an injury without any nerve damage (also known as reflex sympathetic dystrophy). CRPS type II develops as a result of nerve damage or a particular trauma.
The prognosis of complicated regional pain syndrome varies among individuals. In most situations, CRPS is minor and the patient recovers gradually over time; but, in other cases, the symptoms are severe, resulting in long-term impairment. CRPS affects men and women equally, however, women are more likely to be affected.
Complex Regional Pain Syndrome (CRPS) has an unknown origin. CRPS is caused by an accident or trauma in more than 90% of patients. Common causes of injury include leg immobility, soft tissue damage, fracture, sprain, or needle stick injuries induced by medical procedures. In CRPS patients, peripheral nerve defects include unmyelinated and poorly myelinated nerve fibres in the axon area, which generates unusual neurological symptoms.
Increased levels of inflammatory substances such as cytokines in CRPS tissue are frequent in people with inflammatory and autoimmune diseases. The genetic propensity to Complex Regional Pain Syndrome remains unknown. A research on the familial incidence of CRPS in Dutch patients discovered that CRPS can be familial, albeit the pattern of inheritance was unknown. The number of symptoms as well as the individual's medical history influence the diagnosis of CRPS. There are just a few diagnostic procedures for CRPS.
Females are three times more likely than boys to be affected, according to incidence estimates. According to study, one out of every 3,800 people in the UK suffers with CRPS. Therapy (rehabilitation therapy, psychotherapy) or medications such as nonsteroidal anti-inflammatory drugs, corticosteroids, and others can be used to treat CRPS.
Complex Regional Pain Syndrome (CRPS) Demand Analysis (2016 to 2021) Vs Market Outlook (2023 to 2030)
According to a Pharmanucleus analysis, global demand for complex regional pain syndrome (CRPS) is expected to grow at a CAGR of 2.2% between 2023 and 2030, reaching a total of US$ 126.7 Million in 2030. From 2016 through 2021, sales increased significantly at a CAGR of 1.5%.
According to the National Institute of Neurological Disorders and Stroke (NINDS), CRPS is more common in women and can develop at any age. Furthermore, 90% of the cases were the result of trauma or injury. As a result, the rising number of people suffering from chronic pain promotes market expansion.
Growth in R&D investment by both private and public institutions, as well as favourable government legislation, are some of the main drivers expected to drive the industry in the coming years. For example, the Worldwide Research Foundation for RDS/CRPS established a worldwide research network to educate medical professionals and support research.
Which are Some Prominent Drivers of Complex Regional Pain syndrome (CRPS) Market?
Growing Number of People Suffering from Chronic Pain to Boost Demand
There are presently no drugs approved by the FDA in the United States for the treatment of Complex Regional Pain Syndrome. In contrast, physicians suggested treatment and drugs to alleviate persistent pain.
The Food and medicine Administration of the United States recently designated Neridronic acid as a breakthrough medicine in clinical trials for Complex Regional Pain Syndrome. The treatment has also received Fast-track and orphan drug designations from the FDA. Intense research & development, a growth in the number of CRPS cases, and the successful completion of clinical trials are projected to propel the complex regional pain syndrome market forward.
During the forecast period, the growing number of non-profit activities, increased R&D investments by commercial and public organizations, and numerous government initiatives to promote disease awareness are expected to fuel the expansion. of the market. The USA Pain Foundation, for example, is a nonprofit organization dedicated to helping people with chronic pain. The USA Pain Foundation's mission is to empower, educate, and connect people with serious chronic illnesses.
Rising R&D activities and FDA new drug approvals are expected to drive the market growth over the projected period. For example, in September 2021, the FDA granted orphan drug designation to Soin Therapeutics, an Ohio-based pharmaceutical company, for low-dose naltrexone (LDN) to treat complex regional pain syndrome (CRPS).
What are the Challenges Faced by the Complex Regional Pain syndrome (CRPS) Market?
Tight Regulatory Approval and High Medicine Costs to Hinder Market Growth
In the near future, stringent regulatory approvals and high drug costs may limit the growth of the Regional Pain Syndrome Complex Market. In addition to this, a lack of in-depth knowledge about CRPS, a shortage of medical and behavioral pain management professionals, and a shortage of effective treatment choices are the major challenges hampering the growth of the Regional Pain Syndrome Complex market. . Additionally, in poorer countries, a lack of information about the target disease may limit market growth.
Region-Wise Insights
How Will the Complex Regional Pain Syndrome (CRPS) Business Expand Across North America?
Patients' Increased Awareness of Disease Remittance Therapy Creating Opportunities for Complex Regional Pain Syndrome (CRPS) Manufacturers
North America is a major income producer on a worldwide scale and is at the forefront of regional growth. Patients' rising awareness of sickness remittance therapy, the increasing prevalence of CRPS, and high public and private healthcare spending are driving the region's growth.
Revenue growth in North America will most likely be driven by simple access to high-quality healthcare, strong reimbursement policies, a robust clinical pipeline, and the approval of innovative drugs. Increased patient comprehension of disease remittance therapy, rising CRPS prevalence, and high public and private healthcare spending are propelling market growth in these areas.
Easy access to high-quality healthcare, strong clinical pipeline, and approval of innovative drugs are expected to drive the expansion of the market in North America. Thus, due to the aforementioned reasons, North America is expected to possess a market share of 58.5% in 2023, registering a CAGR of 2.1% for the complex regional pain syndrome (CRPS) market during the period. evaluation 2023 to 2030.
How will Asia Pacific Create Growth Opportunities for the Complex Regional Pain Syndrome (CRPS) Market?
Increasing Number of Patients Fueling Rapid Adoption
Asia Pacific is predicted to be the fastest-growing market throughout the forecast period. The number of patients in the region is increasing as more people move to cities. This, in conjunction with increased healthcare spending, is projected to propel the Asia Pacific market. Favourable regulatory requirements for drug approval are predicted to boost demand for the regional market throughout the forecast period.
The primary strategies used by leading players in the global complex regional pain syndrome (CRPS) market have been an expansion into emerging markets and a greater emphasis on early diagnosis, screening, monitoring, and pharmaceutical clinical research. As a result, Asia Pacific is estimated to capture 35% of the market in 2023.
Category-Wise Insights
Which Therapy Type is in High Demand in the Complex Regional Pain Syndrome (CRPS)?
Drug-based Therapy to Remain highly sought after
By type of therapy, drug therapy accounted for a larger proportion of the complex regional pain syndrome (CRPS) market in 2020. This is primarily driven by an increase in the prevalence of several forms of chronic pain, such as low back pain, severe headache or migraine pain and facial discomfort.
Due to increasing elderly population across the world, sedentary lifestyle and increasing number of surgical operations, the analgesics market is expected to grow throughout the forecast period. Thus, by therapy type, drugs are expected to grow at a CAGR of 2% in the complex regional pain syndrome (CRPS) market over the sales indicator period of 2023 to 2030.
Which is the Leading Distribution Channel in the Complex Regional Pain Syndrome (CRPS) Market?
The Hospital Pharmacy Category is witnessing Huge Demand in the Complex Regional Pain Syndrome (CRPS) systems Market
Based on end-use, the hospital pharmacy category is expected to grow at the fastest rate in the market over the forecast period. Hospitals are the top consumer of chronic pain treatment products, accounting for the largest market share of the market in 2020. Pain management strategies are increasingly common in hospitals, especially for post pain. -surgical. Due to the increasing number of surgeries worldwide, hospital pharmacy is expected to continue to generate strong demand for Complex Regional Pain Syndrome (CRPS).
The most frequent complex regional pain syndrome (CRPS) procedures are used in hospitals, particularly for post-surgical pain, where the cost of monitoring and managing side effects produces a strong demand for pharmaceuticals and technology for CRPS. Thus, the hospital pharmacy distribution channel is predicted to have the biggest market share for the complex regional pain syndrome (CRPS) market from 2023 to 2030.
Start-ups for Complex Regional Pain Syndrome (CRPS) Market
Key startup players in the Complex Regional Pain Syndrome (CRPS) market are:
- Brazos Biomedical (TENS) Transcutaneous Electrical Nerve Stimulation: To treat pain, the transcutaneous electrical nerve stimulation therapy stimulates muscles and nerves with tiny electrical pulses given through specialised pads. When electricity affects the nervous system, pain signals travelling between the fibres and the brain are disrupted. These devices are small and portable, providing pain relief to the patient's location.
Brazos Biomedical is a startup in the United States that creates wearable, holo-cephalic medical equipment. To relieve migraine discomfort, the start-up's technology electrically stimulates the trigeminal and occipital nerves. A non-invasive therapeutic technique may aid in the alleviation of an unmet medical need.
- Nalu Medical- Spinal Cord Stimulation
Before they reach the brain, pain impulses are intercepted and inhibited by the spinal cord stimulation system. This method makes use of a tiny device that, like a pacemaker, sends electrical pulses to the spinal cord. This assists patients in managing chronic pain more efficiently and minimises their reliance on narcotic medications.
Nalu Medical is a US-based firm that is developing an implanted medical device. It is used as an adjunct treatment for those who have persistent pain in their trunk or limbs. The company also provides an External experiment Stimulator (ETS) for use during a Spinal Cord Stimulation (SCS) experiment before implanting the permanent device.
Market Competition
Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc. Mylan N.V., Teva Pharmaceutical Industries Ltd., AbbVie, ACTAVIS, Zydus Pharmaceuticals, Inc., Sandoz, and Janssen Global Services, LL., are among the companies involved.
Recent Developments in the Complex Regional Pain Syndrome (CRPS) Market
- In August 2023, GSK plc announced that the New Drug Application (NDA) for momelotinib, a potential new medicine with a proposed differentiated mechanism of action that may address the significant unmet medical needs of myelofibrosis patients with anemia, had been accepted by the US Food and Drug Administration (FDA).
In June 2023, Mallinckrodt plc, a global biopharmaceutical company announced the resubmission of the Company's New Drug Application (NDA) to the USA Food and Drug Administration (FDA) for the investigational agent terlipressin to treat adults with hepatorenal syndrome (HRS), an acute and life-threatening condition with no FDA-approved treatment.